Skip to main content
. 2019 Apr 6;17(4):215. doi: 10.3390/md17040215

Figure 2.

Figure 2

Effects of phomaketide A on human LECs tube formation, migration, and cytotoxicity. Cells were treated with the indicated concentrations of phomaketide A for 8 h. Capillary-like structure formation (A) and cell migration (B) were examined by tube formation and Transwell assays, respectively (N = 4–6). (C) ImageJ software was used to validate the lymphangiogenic functions of phomaketide A. (D) Cells were treated with phomaketide A for 24 h, then cytotoxicity was evaluated by lactate dehydrogenase (LDH) assay (N = 3). Data are expressed as the mean ± SEM. * p < 0.05 compared with the control (CTL) group.